nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Cytarabine—Gemcitabine—urinary bladder cancer	0.422	0.513	CrCrCtD
Regadenoson—Azacitidine—Gemcitabine—urinary bladder cancer	0.401	0.487	CrCrCtD
Regadenoson—Cytarabine—POLB—urinary bladder cancer	0.00423	0.452	CrCbGaD
Regadenoson—Clofarabine—RRM2—urinary bladder cancer	0.0027	0.288	CrCbGaD
Regadenoson—Cladribine—RRM2—urinary bladder cancer	0.00155	0.166	CrCbGaD
Regadenoson—Adenosine monophosphate—SRC—urinary bladder cancer	0.000887	0.0947	CrCbGaD
Regadenoson—Skin disorder—Cisplatin—urinary bladder cancer	0.000286	0.0017	CcSEcCtD
Regadenoson—Insomnia—Gemcitabine—urinary bladder cancer	0.000286	0.0017	CcSEcCtD
Regadenoson—Hypertension—Etoposide—urinary bladder cancer	0.000285	0.0017	CcSEcCtD
Regadenoson—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000285	0.00169	CcSEcCtD
Regadenoson—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000285	0.00169	CcSEcCtD
Regadenoson—Asthma—Methotrexate—urinary bladder cancer	0.000284	0.00169	CcSEcCtD
Regadenoson—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000284	0.00169	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000283	0.00168	CcSEcCtD
Regadenoson—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000282	0.00168	CcSEcCtD
Regadenoson—Chest pain—Etoposide—urinary bladder cancer	0.000281	0.00168	CcSEcCtD
Regadenoson—Insomnia—Fluorouracil—urinary bladder cancer	0.000281	0.00167	CcSEcCtD
Regadenoson—Somnolence—Gemcitabine—urinary bladder cancer	0.000281	0.00167	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00028	0.00166	CcSEcCtD
Regadenoson—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000279	0.00166	CcSEcCtD
Regadenoson—Discomfort—Etoposide—urinary bladder cancer	0.000278	0.00166	CcSEcCtD
Regadenoson—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000277	0.00165	CcSEcCtD
Regadenoson—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000277	0.00165	CcSEcCtD
Regadenoson—Somnolence—Fluorouracil—urinary bladder cancer	0.000276	0.00164	CcSEcCtD
Regadenoson—Hypotension—Cisplatin—urinary bladder cancer	0.000275	0.00164	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000273	0.00162	CcSEcCtD
Regadenoson—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000272	0.00162	CcSEcCtD
Regadenoson—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000271	0.00161	CcSEcCtD
Regadenoson—Pain—Gemcitabine—urinary bladder cancer	0.00027	0.00161	CcSEcCtD
Regadenoson—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00027	0.00161	CcSEcCtD
Regadenoson—Asthenia—Thiotepa—urinary bladder cancer	0.000269	0.0016	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000268	0.0016	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000268	0.0016	CcSEcCtD
Regadenoson—Abdominal distension—Epirubicin—urinary bladder cancer	0.000268	0.00159	CcSEcCtD
Regadenoson—Asthma—Epirubicin—urinary bladder cancer	0.000266	0.00158	CcSEcCtD
Regadenoson—Pain—Fluorouracil—urinary bladder cancer	0.000266	0.00158	CcSEcCtD
Regadenoson—Paraesthesia—Cisplatin—urinary bladder cancer	0.000264	0.00157	CcSEcCtD
Regadenoson—Tachycardia—Etoposide—urinary bladder cancer	0.000263	0.00157	CcSEcCtD
Regadenoson—Dyspnoea—Cisplatin—urinary bladder cancer	0.000263	0.00156	CcSEcCtD
Regadenoson—Skin disorder—Etoposide—urinary bladder cancer	0.000262	0.00156	CcSEcCtD
Regadenoson—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000261	0.00155	CcSEcCtD
Regadenoson—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00026	0.00155	CcSEcCtD
Regadenoson—Angina pectoris—Epirubicin—urinary bladder cancer	0.000259	0.00154	CcSEcCtD
Regadenoson—Diarrhoea—Thiotepa—urinary bladder cancer	0.000257	0.00153	CcSEcCtD
Regadenoson—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000256	0.00152	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000254	0.00151	CcSEcCtD
Regadenoson—Hypotension—Etoposide—urinary bladder cancer	0.000252	0.0015	CcSEcCtD
Regadenoson—Pain—Cisplatin—urinary bladder cancer	0.000252	0.0015	CcSEcCtD
Regadenoson—Renal failure—Methotrexate—urinary bladder cancer	0.000249	0.00148	CcSEcCtD
Regadenoson—Dizziness—Thiotepa—urinary bladder cancer	0.000248	0.00148	CcSEcCtD
Regadenoson—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000248	0.00147	CcSEcCtD
Regadenoson—Urticaria—Fluorouracil—urinary bladder cancer	0.000247	0.00147	CcSEcCtD
Regadenoson—Asthma—Doxorubicin—urinary bladder cancer	0.000246	0.00146	CcSEcCtD
Regadenoson—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000243	0.00144	CcSEcCtD
Regadenoson—Paraesthesia—Etoposide—urinary bladder cancer	0.000242	0.00144	CcSEcCtD
Regadenoson—Dyspnoea—Etoposide—urinary bladder cancer	0.000241	0.00143	CcSEcCtD
Regadenoson—Somnolence—Etoposide—urinary bladder cancer	0.00024	0.00143	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—urinary bladder cancer	0.00024	0.00143	CcSEcCtD
Regadenoson—Vomiting—Thiotepa—urinary bladder cancer	0.000239	0.00142	CcSEcCtD
Regadenoson—Rash—Thiotepa—urinary bladder cancer	0.000237	0.00141	CcSEcCtD
Regadenoson—Dermatitis—Thiotepa—urinary bladder cancer	0.000237	0.00141	CcSEcCtD
Regadenoson—Headache—Thiotepa—urinary bladder cancer	0.000235	0.0014	CcSEcCtD
Regadenoson—Renal failure—Epirubicin—urinary bladder cancer	0.000233	0.00139	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000233	0.00139	CcSEcCtD
Regadenoson—Pain—Etoposide—urinary bladder cancer	0.000231	0.00137	CcSEcCtD
Regadenoson—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000229	0.00136	CcSEcCtD
Regadenoson—Asthenia—Gemcitabine—urinary bladder cancer	0.000227	0.00135	CcSEcCtD
Regadenoson—Nausea—Thiotepa—urinary bladder cancer	0.000223	0.00133	CcSEcCtD
Regadenoson—Feeling abnormal—Etoposide—urinary bladder cancer	0.000222	0.00132	CcSEcCtD
Regadenoson—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000221	0.00131	CcSEcCtD
Regadenoson—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000217	0.00129	CcSEcCtD
Regadenoson—Bradycardia—Epirubicin—urinary bladder cancer	0.000217	0.00129	CcSEcCtD
Regadenoson—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000216	0.00129	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—urinary bladder cancer	0.000216	0.00128	CcSEcCtD
Regadenoson—Urticaria—Etoposide—urinary bladder cancer	0.000214	0.00128	CcSEcCtD
Regadenoson—Abdominal pain—Etoposide—urinary bladder cancer	0.000213	0.00127	CcSEcCtD
Regadenoson—Eye disorder—Methotrexate—urinary bladder cancer	0.000213	0.00127	CcSEcCtD
Regadenoson—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000213	0.00127	CcSEcCtD
Regadenoson—Tinnitus—Methotrexate—urinary bladder cancer	0.000212	0.00126	CcSEcCtD
Regadenoson—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000212	0.00126	CcSEcCtD
Regadenoson—Asthenia—Cisplatin—urinary bladder cancer	0.000211	0.00126	CcSEcCtD
Regadenoson—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000211	0.00126	CcSEcCtD
Regadenoson—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000209	0.00125	CcSEcCtD
Regadenoson—Angiopathy—Methotrexate—urinary bladder cancer	0.000206	0.00123	CcSEcCtD
Regadenoson—Immune system disorder—Methotrexate—urinary bladder cancer	0.000205	0.00122	CcSEcCtD
Regadenoson—Dizziness—Fluorouracil—urinary bladder cancer	0.000205	0.00122	CcSEcCtD
Regadenoson—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000205	0.00122	CcSEcCtD
Regadenoson—Diarrhoea—Cisplatin—urinary bladder cancer	0.000202	0.0012	CcSEcCtD
Regadenoson—Vomiting—Gemcitabine—urinary bladder cancer	0.000201	0.0012	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—urinary bladder cancer	0.000201	0.00119	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—urinary bladder cancer	0.000199	0.00119	CcSEcCtD
Regadenoson—Rash—Gemcitabine—urinary bladder cancer	0.000199	0.00119	CcSEcCtD
Regadenoson—Dermatitis—Gemcitabine—urinary bladder cancer	0.000199	0.00118	CcSEcCtD
Regadenoson—Eye disorder—Epirubicin—urinary bladder cancer	0.000199	0.00118	CcSEcCtD
Regadenoson—Hypersensitivity—Etoposide—urinary bladder cancer	0.000199	0.00118	CcSEcCtD
Regadenoson—Tinnitus—Epirubicin—urinary bladder cancer	0.000198	0.00118	CcSEcCtD
Regadenoson—Erythema—Methotrexate—urinary bladder cancer	0.000198	0.00118	CcSEcCtD
Regadenoson—Headache—Gemcitabine—urinary bladder cancer	0.000198	0.00118	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000198	0.00118	CcSEcCtD
Regadenoson—Flushing—Epirubicin—urinary bladder cancer	0.000198	0.00118	CcSEcCtD
Regadenoson—Vomiting—Fluorouracil—urinary bladder cancer	0.000198	0.00118	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000196	0.00117	CcSEcCtD
Regadenoson—Rash—Fluorouracil—urinary bladder cancer	0.000196	0.00117	CcSEcCtD
Regadenoson—Dermatitis—Fluorouracil—urinary bladder cancer	0.000196	0.00116	CcSEcCtD
Regadenoson—Headache—Fluorouracil—urinary bladder cancer	0.000195	0.00116	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—urinary bladder cancer	0.000194	0.00115	CcSEcCtD
Regadenoson—Asthenia—Etoposide—urinary bladder cancer	0.000194	0.00115	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000194	0.00115	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—urinary bladder cancer	0.000193	0.00115	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—urinary bladder cancer	0.000192	0.00114	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000192	0.00114	CcSEcCtD
Regadenoson—Nausea—Gemcitabine—urinary bladder cancer	0.000188	0.00112	CcSEcCtD
Regadenoson—Vomiting—Cisplatin—urinary bladder cancer	0.000187	0.00111	CcSEcCtD
Regadenoson—Vision blurred—Methotrexate—urinary bladder cancer	0.000187	0.00111	CcSEcCtD
Regadenoson—Mental disorder—Epirubicin—urinary bladder cancer	0.000187	0.00111	CcSEcCtD
Regadenoson—Rash—Cisplatin—urinary bladder cancer	0.000186	0.00111	CcSEcCtD
Regadenoson—Dermatitis—Cisplatin—urinary bladder cancer	0.000186	0.0011	CcSEcCtD
Regadenoson—Erythema—Epirubicin—urinary bladder cancer	0.000185	0.0011	CcSEcCtD
Regadenoson—Diarrhoea—Etoposide—urinary bladder cancer	0.000185	0.0011	CcSEcCtD
Regadenoson—Nausea—Fluorouracil—urinary bladder cancer	0.000185	0.0011	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—urinary bladder cancer	0.000184	0.0011	CcSEcCtD
Regadenoson—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000184	0.00109	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—urinary bladder cancer	0.000184	0.00109	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—urinary bladder cancer	0.000183	0.00109	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000183	0.00109	CcSEcCtD
Regadenoson—Dysgeusia—Epirubicin—urinary bladder cancer	0.000181	0.00108	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—urinary bladder cancer	0.000179	0.00106	CcSEcCtD
Regadenoson—Malaise—Methotrexate—urinary bladder cancer	0.000179	0.00106	CcSEcCtD
Regadenoson—Dizziness—Etoposide—urinary bladder cancer	0.000178	0.00106	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000178	0.00106	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000178	0.00106	CcSEcCtD
Regadenoson—Nausea—Cisplatin—urinary bladder cancer	0.000175	0.00104	CcSEcCtD
Regadenoson—Vision blurred—Epirubicin—urinary bladder cancer	0.000175	0.00104	CcSEcCtD
Regadenoson—Cough—Methotrexate—urinary bladder cancer	0.000173	0.00103	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—urinary bladder cancer	0.000173	0.00103	CcSEcCtD
Regadenoson—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000172	0.00102	CcSEcCtD
Regadenoson—Convulsion—Methotrexate—urinary bladder cancer	0.000172	0.00102	CcSEcCtD
Regadenoson—Vomiting—Etoposide—urinary bladder cancer	0.000172	0.00102	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—urinary bladder cancer	0.000171	0.00102	CcSEcCtD
Regadenoson—Rash—Etoposide—urinary bladder cancer	0.00017	0.00101	CcSEcCtD
Regadenoson—Dermatitis—Etoposide—urinary bladder cancer	0.00017	0.00101	CcSEcCtD
Regadenoson—Headache—Etoposide—urinary bladder cancer	0.000169	0.00101	CcSEcCtD
Regadenoson—Chest pain—Methotrexate—urinary bladder cancer	0.000169	0.001	CcSEcCtD
Regadenoson—Myalgia—Methotrexate—urinary bladder cancer	0.000169	0.001	CcSEcCtD
Regadenoson—Arthralgia—Methotrexate—urinary bladder cancer	0.000169	0.001	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000168	0.000999	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000167	0.000996	CcSEcCtD
Regadenoson—Malaise—Epirubicin—urinary bladder cancer	0.000167	0.000995	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—urinary bladder cancer	0.000167	0.000991	CcSEcCtD
Regadenoson—Syncope—Epirubicin—urinary bladder cancer	0.000166	0.000989	CcSEcCtD
Regadenoson—Palpitations—Epirubicin—urinary bladder cancer	0.000164	0.000975	CcSEcCtD
Regadenoson—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000163	0.000969	CcSEcCtD
Regadenoson—Cough—Epirubicin—urinary bladder cancer	0.000162	0.000962	CcSEcCtD
Regadenoson—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000162	0.000962	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—urinary bladder cancer	0.000162	0.000962	CcSEcCtD
Regadenoson—Convulsion—Epirubicin—urinary bladder cancer	0.000161	0.000956	CcSEcCtD
Regadenoson—Nausea—Etoposide—urinary bladder cancer	0.00016	0.000954	CcSEcCtD
Regadenoson—Hypertension—Epirubicin—urinary bladder cancer	0.00016	0.000952	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000159	0.000947	CcSEcCtD
Regadenoson—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000158	0.000943	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—urinary bladder cancer	0.000158	0.000939	CcSEcCtD
Regadenoson—Chest pain—Epirubicin—urinary bladder cancer	0.000158	0.000939	CcSEcCtD
Regadenoson—Myalgia—Epirubicin—urinary bladder cancer	0.000158	0.000939	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—urinary bladder cancer	0.000157	0.000936	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—urinary bladder cancer	0.000157	0.000934	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000157	0.000933	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000156	0.00093	CcSEcCtD
Regadenoson—Discomfort—Epirubicin—urinary bladder cancer	0.000156	0.000928	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—urinary bladder cancer	0.000155	0.00092	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—urinary bladder cancer	0.000154	0.000915	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—urinary bladder cancer	0.000152	0.000902	CcSEcCtD
Regadenoson—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000151	0.0009	CcSEcCtD
Regadenoson—Hypotension—Methotrexate—urinary bladder cancer	0.000151	0.000899	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000151	0.000897	CcSEcCtD
Regadenoson—Cough—Doxorubicin—urinary bladder cancer	0.00015	0.000891	CcSEcCtD
Regadenoson—Shock—Epirubicin—urinary bladder cancer	0.000149	0.000886	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—urinary bladder cancer	0.000149	0.000884	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000148	0.000883	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—urinary bladder cancer	0.000148	0.000881	CcSEcCtD
Regadenoson—Tachycardia—Epirubicin—urinary bladder cancer	0.000148	0.000879	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000147	0.000876	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—urinary bladder cancer	0.000147	0.000874	CcSEcCtD
Regadenoson—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000146	0.00087	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—urinary bladder cancer	0.000146	0.00087	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—urinary bladder cancer	0.000146	0.000869	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—urinary bladder cancer	0.000146	0.000869	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—urinary bladder cancer	0.000146	0.000869	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—urinary bladder cancer	0.000145	0.000866	CcSEcCtD
Regadenoson—Paraesthesia—Methotrexate—urinary bladder cancer	0.000145	0.000864	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000145	0.000863	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—urinary bladder cancer	0.000144	0.000858	CcSEcCtD
Regadenoson—Dyspnoea—Methotrexate—urinary bladder cancer	0.000144	0.000858	CcSEcCtD
Regadenoson—Somnolence—Methotrexate—urinary bladder cancer	0.000144	0.000855	CcSEcCtD
Regadenoson—Hypotension—Epirubicin—urinary bladder cancer	0.000141	0.000841	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00014	0.000833	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00014	0.00083	CcSEcCtD
Regadenoson—Pain—Methotrexate—urinary bladder cancer	0.000138	0.000823	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000138	0.00082	CcSEcCtD
Regadenoson—Shock—Doxorubicin—urinary bladder cancer	0.000138	0.000819	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000137	0.000817	CcSEcCtD
Regadenoson—Insomnia—Epirubicin—urinary bladder cancer	0.000137	0.000814	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—urinary bladder cancer	0.000137	0.000813	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—urinary bladder cancer	0.000136	0.000809	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—urinary bladder cancer	0.000136	0.000808	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000135	0.000805	CcSEcCtD
Regadenoson—Dyspnoea—Epirubicin—urinary bladder cancer	0.000135	0.000803	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—urinary bladder cancer	0.000134	0.0008	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000133	0.000793	CcSEcCtD
Regadenoson—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000132	0.000787	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—urinary bladder cancer	0.000131	0.000778	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000131	0.000777	CcSEcCtD
Regadenoson—Pain—Epirubicin—urinary bladder cancer	0.000129	0.00077	CcSEcCtD
Regadenoson—Urticaria—Methotrexate—urinary bladder cancer	0.000128	0.000764	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—urinary bladder cancer	0.000128	0.00076	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000127	0.000759	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—urinary bladder cancer	0.000127	0.000753	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000126	0.000748	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000125	0.000743	CcSEcCtD
Regadenoson—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000125	0.000742	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—urinary bladder cancer	0.000124	0.00074	CcSEcCtD
Regadenoson—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000124	0.000736	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000121	0.000719	CcSEcCtD
Regadenoson—Urticaria—Epirubicin—urinary bladder cancer	0.00012	0.000715	CcSEcCtD
Regadenoson—Pain—Doxorubicin—urinary bladder cancer	0.00012	0.000712	CcSEcCtD
Regadenoson—Abdominal pain—Epirubicin—urinary bladder cancer	0.00012	0.000712	CcSEcCtD
Regadenoson—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000119	0.000709	CcSEcCtD
Regadenoson—Asthenia—Methotrexate—urinary bladder cancer	0.000116	0.00069	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000115	0.000686	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000114	0.000681	CcSEcCtD
Regadenoson—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000111	0.000663	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—urinary bladder cancer	0.000111	0.000662	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000111	0.000658	CcSEcCtD
Regadenoson—Diarrhoea—Methotrexate—urinary bladder cancer	0.000111	0.000658	CcSEcCtD
Regadenoson—Asthenia—Epirubicin—urinary bladder cancer	0.000109	0.000646	CcSEcCtD
Regadenoson—Dizziness—Methotrexate—urinary bladder cancer	0.000107	0.000636	CcSEcCtD
Regadenoson—Diarrhoea—Epirubicin—urinary bladder cancer	0.000103	0.000616	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000103	0.000614	CcSEcCtD
Regadenoson—Vomiting—Methotrexate—urinary bladder cancer	0.000103	0.000612	CcSEcCtD
Regadenoson—Rash—Methotrexate—urinary bladder cancer	0.000102	0.000606	CcSEcCtD
Regadenoson—Dermatitis—Methotrexate—urinary bladder cancer	0.000102	0.000606	CcSEcCtD
Regadenoson—Headache—Methotrexate—urinary bladder cancer	0.000101	0.000603	CcSEcCtD
Regadenoson—Asthenia—Doxorubicin—urinary bladder cancer	0.0001	0.000598	CcSEcCtD
Regadenoson—Dizziness—Epirubicin—urinary bladder cancer	0.0001	0.000595	CcSEcCtD
Regadenoson—Vomiting—Epirubicin—urinary bladder cancer	9.62e-05	0.000572	CcSEcCtD
Regadenoson—Nausea—Methotrexate—urinary bladder cancer	9.6e-05	0.000571	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—urinary bladder cancer	9.57e-05	0.00057	CcSEcCtD
Regadenoson—Rash—Epirubicin—urinary bladder cancer	9.54e-05	0.000568	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—urinary bladder cancer	9.53e-05	0.000567	CcSEcCtD
Regadenoson—Headache—Epirubicin—urinary bladder cancer	9.47e-05	0.000564	CcSEcCtD
Regadenoson—Dizziness—Doxorubicin—urinary bladder cancer	9.25e-05	0.000551	CcSEcCtD
Regadenoson—Nausea—Epirubicin—urinary bladder cancer	8.98e-05	0.000535	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—urinary bladder cancer	8.9e-05	0.00053	CcSEcCtD
Regadenoson—Rash—Doxorubicin—urinary bladder cancer	8.82e-05	0.000525	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—urinary bladder cancer	8.82e-05	0.000525	CcSEcCtD
Regadenoson—Headache—Doxorubicin—urinary bladder cancer	8.77e-05	0.000522	CcSEcCtD
Regadenoson—Nausea—Doxorubicin—urinary bladder cancer	8.31e-05	0.000495	CcSEcCtD
